Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

RARE PHOTOS: Corcept therapeutics s return on capital employed overview | Rare Historical Photos

According to Benzinga Pro, during Q4, Corcept Therapeutics (NASDAQ:CORT) earned $32.05 million, a 5.19% increase from the preceding quarter. Corcept Therapeutics also posted a total of $98.82 million in sales, a 2.8% increase since Q3. Corcept Therapeutics earned $30.47 million, and sales totaled $96.13 million in Q3.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.